Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Emplicure has formed Nomination Comittee

Emplicure

EMPLICURE HAS FORMED NOMINATION COMITTEE

Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in May 2023 is formed. The Nomination Committee  consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to give preference for more shareholders.

The Nomination Committee for the 2023 AGM is:

  • Thomas Lundqvist
  • Henrik Didner, for Monesi Förvaltnings AB
  • Peyman Pournouri
  • Gisela Sitbon (Chairman of the Board of Directors, Emplicure AB)

The Nomination Committee represents 47.7% of the votes in Emplicure.

The shores of the Nomination Committee:

The Nomination Committee shall, in short, prepare suggestions for the following to the AGM:

  • Election of Board of Directors (BoD)
  • Election of av Chairman of the Board
  • Resolution regarding number of auditors and auditor election
  • Remunerations for the BoD and the auditors
  • Principles that shall apply to the composition and work of the nomination committee for the next AGM

Primary contact for the Nomination Committee

Proposals by shareholders to the Nomination Committee may be submitted to the Chairman of the Board of Emplicure AB, Gisela Sitbon (gisela@sitbon.nu).

Certified Adviser

Certified Adviser is Erik Penser Bank AB.

The following documents can be retrieved from beQuoted
PM-Emplicure-Nomination-Committee 2023.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.